Gilead Sciences, Inc. (GILD) Stock Price & How to Invest

Gilead Sciences is a large biopharmaceutical company best known for its leadership in treating viral diseases, especially HIV. Its HIV franchise, anchored by widely used single-tablet regimens like Biktarvy and the long-acting prevention drug for pre-exposure prophylaxis, generates the bulk of its revenue and is a global standard of care. Gilead also has a significant presence in liver diseases, including hepatitis B and C, where its cures transformed treatment, and in COVID-19 with the antiviral remdesivir. More recently, Gilead has expanded into oncology through acquisitions, building a portfolio in cell therapy (CAR-T) and antibody-drug conjugates for cancers such as breast and bladder cancer. The company makes money by selling these prescription medicines worldwide, supported by patents and strong pricing. Headquartered in Foster City, California, Gilead generates substantial cash flow from its HIV base, pays a solid dividend, and is investing to diversify into oncology and other areas as it manages future patent expirations.

Gilead is heavily dependent on its HIV franchise, so any new competition, pricing pressure, or patent expiration there is a major risk. Hepatitis C revenue declined sharply after its cures shrank the patient pool, illustrating how success can erode markets. Its oncology expansion has been costly and uneven, with some acquired programs underperforming expectations, raising questions about capital allocation. Drug development is risky, with frequent trial failures. The company faces regulatory, reimbursement, and drug-pricing policy pressures, including in the US. Litigation and patent challenges can arise. Diversifying away from virology successfully is essential but unproven at scale, leaving the long-term growth profile dependent on pipeline execution beyond its core HIV business.

27 analysts publish price targets on GILD, averaging $157.15 against a $133.94 price as of July 2026, or +17.3%. The published targets run from $120.00 to $180.00, a moderate spread, and the ratings split 22 buy, 7 hold, 0 sell. Over the last six months there have been 2 raises and 7 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full GILD forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Gilead Sciences, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Dominant HIV franchise. Gilead leads the global HIV market with widely prescribed regimens like Biktarvy and long-acting prevention options. The most optimistic published target, $180.00, assumes this works close to its best case.

The case against. Gilead is heavily dependent on its HIV franchise, so any new competition, pricing pressure, or patent expiration there is a major risk. The most pessimistic target, $120.00, is roughly what GILD is worth if this bites instead.

Read the full bull and bear case on GILD, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Gilead Sciences, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$28 to 30 billion
• Operating margin: ~thirties percent (varies with charges)
• Net income (TTM): ~variable, affected by acquisition charges
• Dividend yield: ~3 to 4%
• Free cash flow: ~strong, several billion annually
• HIV revenue share: ~majority of product sales
• Market cap: ~$100 billion or more

Gilead is valued as a mature, cash-generative biopharma with a dominant HIV base and a solid dividend, rather than a high-growth name. Investors weigh durable virology cash flows and capital return against limited overall growth and uncertainty in oncology. Reported earnings can swing with acquisition-related charges, so investors often focus on underlying product revenue and free cash flow.

If you want GILD exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

These are the investment theses GILD naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Other names that sit close to GILD: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get GILD exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (USMV, VHT, BBH), which spreads the position across many companies. Or build it into a focused thematic portfolio, so GILD sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where GILD fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Gilead Sciences (GILD) is an income-oriented biopharma anchored by a standard-of-care HIV business that funds research, acquisitions, and a high dividend yield. In a portfolio it behaves as a defensive healthcare holding with limited overall growth, where the payoff hinges on managing HIV patent cliffs and proving its costly oncology expansion at scale.

Whether GILD is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is GILD a buy or a sell?, and where the stock could go from here in the GILD stock forecast.

For income investors, whether GILD pays a dividend and how the payout looks is covered in does GILD pay a dividend? And to weigh GILD against a peer, read the full side-by-side comparisons: GILD vs VRTX and GILD vs AMGN.